Arrowstreet Capital
APLS

Arrowstreet Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Arrowstreet Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-418,539
Closed -$13.8M – 1437
2021
Q3 		$13.8M Buy
418,539
+297,251
+245% +$16.7M 0.02% 635
2021
Q2 		$7.67M Buy
121,288
+47,888
+65% +$2.47M 0.01% 926
2021
Q1 		$3.15M Buy
+73,400
New +$3.47M ﹤0.01% 1383
2020
Q3 		– Sell
-42,087
Closed -$1.38M – 2314
2020
Q2 		$1.38M Buy
42,087
+2,900
+7% +$93.1K ﹤0.01% 1645
2020
Q1 		$1.05M Sell
39,187
-41,304
-51% -$1.47M ﹤0.01% 1302
2019
Q4 		$2.46M Buy
+80,491
New +$2.23M 0.01% 1070

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Arrowstreet Capital's APLS Position: Q4 2021 in Review

Arrowstreet Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2021, closing a stake of 418,539 shares — an estimated $13.8M sold.

Arrowstreet Capital first reported a position in APLS in Q4 2019 and held it in 6 quarters. The position peaked at $13.8M in Q3 2021. 186 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Arrowstreet Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 418,539 Apellis Pharmaceuticals shares in Q4 2021, an estimated $13.8M.
  • Arrowstreet Capital first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Arrowstreet Capital's Apellis Pharmaceuticals position peaked at $13.8M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Arrowstreet Capital's 13F filing for Q4 2021, filed 14 Feb 2022.